Novo nordisk announces impact from volume based procurement for insulin in china

BagsvÆrd , de n mark, 26 november 2021 – novo nordisk today announced that the company has received the results from the volume based procurement (vbp) tender for insulin in china. the chinese national healthcare security administration has tendered insulin sold at hospitals, and novo nordisk has participated in the tender. all novo nordisk's insulin were included in the tender except for ryzodeg® and xultophy®.
NVO Ratings Summary
NVO Quant Ranking